CN1935274A - Coronary artery medicinal-coating stent - Google Patents
Coronary artery medicinal-coating stent Download PDFInfo
- Publication number
- CN1935274A CN1935274A CN 200610096840 CN200610096840A CN1935274A CN 1935274 A CN1935274 A CN 1935274A CN 200610096840 CN200610096840 CN 200610096840 CN 200610096840 A CN200610096840 A CN 200610096840A CN 1935274 A CN1935274 A CN 1935274A
- Authority
- CN
- China
- Prior art keywords
- ligustrazine
- coating
- support
- stent
- coronary artery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The present invention discloses a coronary artery medicine coating scaffold for inhibiting endometrial hyperplasia and preventing restenosis in the scaffold. It includes dilating scaffold base body and inner coating layer coated on the dilating scaffold base body, the above-mentioned inner coating layer is formed from medicine carrier and ligustrazine, their mass ratio is 3:1-1:3, the above-mentioned inner coating layer is one of methyl acrylate, methyl methacrylate copolymer, polylactic acid, polyglycollic acid, polymonoracemic lactic acid, polylactide-diglycolide polymer, phosphorylcholine, ethyl polyurethane inorganic micropore aluminium oxide and cellulose or their composite.
Description
Technical field
The present invention relates to a kind of human body implant frame, relate in particular to a kind of coronary artery medicinal-coating stent that is used to suppress intimal proliferation and prevention in-stent restenosis.
Background technology
Over year, coronary artery stent implantation becomes a kind of important means that definite curative effect is arranged in the coronary heart disease treatment, more and more be widely used in the treatment of coronary heart disease, but the support postoperative restenosis has limited the development of stenting greatly surplus in the of nearly ten.
Illustrate the Pathophysiology and the pathogenesis of in-stent restenosis, then for preventing the key point of in-stent restenosis.Consistently in recent years think that support is implanted can cause that in early days endothelium strips off, and compositions such as collagen, the vWF factor, fibronectin and laminin are exposed in the blood, promotes platelet adhesion and gathering, and form thrombosis in support; Support is implanted the back to the damage of blood vessel wall or make the fat nucleorhexis, can cause local acute inflammatory reaction; The damage of tremulous pulse also causes the propagation of vascular smooth muscle cell and the hypertrophy of migration and extracellular matrix, and these factors are the main mechanism that in-stent restenosis takes place.The treatment of in-stent restenosis is difficulty comparatively, studies show that recently, and after coronary artery bracket was implanted, it was 28% that the interior ISR of support leads, and in the patient of restenosis high risk factors such as diabetes and small vessel disease change, ISR leads can be up to 50%～80%; Other has report, and different with operational means with Clinical symptoms, radiography result, ISR leads and reaches 10-50% behind the stenting.Therefore, seek a kind of method that can effectively prevent in-stent restenosis clinically, become the focus in the research of intervention property cardiology.
At above-mentioned mechanism, the use of antiplatelet drug and anticoagulant medicine has significantly reduced thrombotic probability clinically, and at the new intima hypertrophy, also once attempts plesioradiotherapy in the blood vessel in recent years, but general effect is not satisfied.
Summary of the invention
The invention provides and a kind ofly can suppress user intimal proliferation and prevention in-stent restenosis, and curative effect height, low, the cheap coronary artery medicinal-coating stent of expense of toxic and side effects.
The present invention adopts following technical scheme:
A kind of coronary artery medicinal-coating stent that is used to suppress intimal proliferation and prevention in-stent restenosis, comprise: expanding support matrix, on expanding support matrix, be coated with undercoating, above-mentioned undercoating is made up of pharmaceutical carrier and ligustrazine, its mass ratio is: 3: 1～1: 3, the said medicine carrier was an acrylic acid methyl ester., methylmethacrylate copolymer, polylactic acid (PLLA), polyglycolic acid, poly--racemic lactic acid, polylactide-co-glycolide polymers, Phosphorylcholine, poly-aethylis carbamas, inorganic micropore aluminium sesquioxide, the compositions of one or more in the cellulose.The present invention also can be coated with external coating on undercoating, this external coating is one or more the composition coating in acrylic acid methyl ester., methylmethacrylate copolymer, polylactic acid (PLLA), polyglycolic acid, poly--racemic lactic acid, polylactide-co-glycolide polymers, Phosphorylcholine, the poly-aethylis carbamas.
Compared with prior art, the present invention has following advantage:
The present invention is an active component with ligustrazine (TMP), and methylmethacrylate copolymer and ligustrazine grains of composition, polyglycolic acid are coated on the support matrix surface successively.Ligustrazine has the effect of restenosis in the potential prevention blood vessel.The mechanism of action of ligustrazine is: 1. antiplatelet aggregation and thrombosis nucleus formation.Ligustrazine suppresses the platelet arachidonic acid metabolic, thereby suppresses the biosynthesis and the biological activity of platelet T XA2 sample material, promotes vascular endothelial cell to produce PGI2 simultaneously again; Platelet increasing cAMP content, Ca2+ on the displacement platelet membrane, its membrane fluidity is strengthened, and block Ca2+, thereby suppress hematoblastic gathering and release reaction platelet activation and prostaglandin metabolism and inhibition platelet mitochondrion oxygen consumption and oxidative phosphorylation; Make calcium ion concentration reduction in the platelet by calcium antagonism, the blocking-up calcium ion is to the metabolism of platelet activation and prostaglandin; Strengthen the NOS activity, the generation of NO in the stimulating platelet.2. suppress vascular smooth muscle cell and fibroblast proliferation.And the main mechanism of in-stent restenosis promptly to be smooth muscle cell proliferation the be main neointimal hyperplasia that comprises extracellular matrix.Ligustrazine has inhibitory action to vascular endothelial cell and smooth muscle cell cultivation, and suppresses the genetic transcription of smooth muscle cell I, III procollagen type, can improve and suppress AS formation related gene such as the isogenic expression of P53, NOS.In the rabbit aorta vascular smooth muscle cell proliferation model of thrombin induction In vitro culture, experimental result confirms the significantly inductive vascular smooth muscle cell c-myc expression of gene protein increase of Trombin inhibiting of ligustrazine, the cell number that makes vascular smooth muscle be in the G1 phase significantly increases, S phase and M phase cell number significantly reduce, thereby suppress smooth muscle cell proliferation.In addition, Angiotensin II can promote the hypertrophy of myocardial cell by 1 mediation of angiotensin receptor hypotype, also can promote the hypertrophy of fibroblast, collagenocyte, vascular cell.Thereby ligustrazine can block AT1 and suppress Angiotensin II to the short loose effect of myocardial cell with to the short proliferative effect of non-myocardial cell.3. blood vessel dilating effect.Endothelin-1 (ET-1) is intensive vaso-excitor material.Most researchs think that the contract mechanism of blood vessel of ET-1 is relevant with the flow of calcium ions of smooth muscle cell, and ligustrazine can resist the blood vessel function that contracts of endothelin-1 (ET-1) by the flow of calcium ions of inhibition smooth muscle cell.In addition, studies show that its vasodilative effect is also relevant with ATP responsive type potassium channel with open small-conductance calcium-activated potassium channel.4. adjusting lipid metabolism, anti peroxidation of lipid.Ligustrazine improves the ability of removing oxygen-derived free radicals by improving the vigor of superoxide dismutase and glutathion peroxidase, reduces lipid peroxidation.5. protect the arteria coronaria endothelium.By reducing body ET level, improve nitric oxide level, improve the endothelial function disorder.In addition, ligustrazine also has effects such as ischemia resisting reperfusion injury, anti-myocardial ischemia reoxygenation injury, promotion myocardial cell energy metabolism.
With respect to rapamycin and paclitaxel coating bracket, the ligustrazine coating bracket has following advantage: at first, the drug toxicity of ligustrazine relative with side effect a little less than.Secondly, the ligustrazine source is convenient, low price.
Description of drawings
Fig. 1 is that support is implanted back 28 days bare bracket groups (BMS) and ligustrazine coating bracket group (TES) histopathological examination contrast figure (H﹠amp; E dyeing * 40), A is the bare bracket picture group among Fig. 1, and B is a ligustrazine coating bracket picture group among Fig. 1, and the arrow indication is a new intima among Fig. 1.
Fig. 2 is that support is implanted back 28 days BMS and TES SABC inspection contrast figure (PCNA dyeing * 400, the arrow indication is a staining cell), and A is the bare bracket picture group among Fig. 2, and B is a ligustrazine coating bracket picture group among Fig. 2, and the arrow indication is a staining cell among Fig. 2.
Fig. 3 is the external scanning electron microscopic observation picture that TES and BMS are carried out, A, B are presented at 1000 times, 2000 of surface before the external TES expansion to show little picture among Fig. 3, and C, D are presented at 1000 times, 2000 of surface after the external TES expansion to show little photo among Fig. 3.
Fig. 4 is that (H﹠amp is measured in the morphology of support vessel segment; E dyeing, the arrow indication is a new intima) picture, A is the bare bracket picture group among Fig. 4, B is a ligustrazine coating bracket picture group among Fig. 2.
Fig. 5-the 1st, support implant back 28 days microphotograpies and show the influence of TMP to myocardium of left ventricle, and A is the bare bracket picture group among Fig. 5-1, and B is a ligustrazine coating bracket picture group among Fig. 5-1.
Fig. 5-the 2nd, support implant back 28 days microphotograpies and show the influence of TMP to support vessel segment perienchyma, and A is the bare bracket picture group among Fig. 5-2, and B is a ligustrazine coating bracket picture group among Fig. 5-2.
Fig. 5-the 3rd, support implant back 28 days microphotograpies and show the influence of TMP to lungs, and A is the bare bracket picture group among Fig. 5-3, and B is a ligustrazine coating bracket picture group among Fig. 5-3.
Fig. 5-the 4th, support implant back 28 days microphotograpies and show the influence of TMP to liver, and A is the bare bracket picture group among Fig. 5-4, and B is a ligustrazine coating bracket picture group among Fig. 5-4.
Fig. 5-the 5th, support implant back 28 days microphotograpies and show the influence of TMP to kidney, and A is the bare bracket picture group among Fig. 5-5, and B is a ligustrazine coating bracket picture group among Fig. 5-5.
Fig. 5-the 6th, support implant back 28 days microphotograpies and show the influence of TMP to spleen, and A is the bare bracket picture group among Fig. 5-6, and B is a ligustrazine coating bracket picture group among Fig. 5-6.
Fig. 6 is a structural representation of the present invention.
Fig. 7 is an A-A of the present invention cross section enlarged drawing.
The specific embodiment
A kind of coronary artery medicinal-coating stent that is used to suppress intimal proliferation and prevention in-stent restenosis, comprise: expanding support matrix 1, on expanding support matrix 1, be coated with undercoating 2, above-mentioned undercoating 2 is made up of pharmaceutical carrier and ligustrazine, its mass ratio is: 3: 1～1: 3, in the present embodiment, its mass ratio can be chosen 3: 1,1: 3 or 2: 2, the said medicine carrier was an acrylic acid methyl ester., methylmethacrylate copolymer, polylactic acid (PLLA), polyglycolic acid, poly--racemic lactic acid, polylactide-co-glycolide polymers, Phosphorylcholine, poly-aethylis carbamas, inorganic micropore aluminium sesquioxide, the compositions of one or more in the cellulose.Present embodiment also can be coated with external coating 3 on undercoating 2, this external coating 3 is one or more the composition coating in acrylic acid methyl ester., methylmethacrylate copolymer, polylactic acid (PLLA), polyglycolic acid, poly--racemic lactic acid, polylactide-co-glycolide polymers, Phosphorylcholine, the poly-aethylis carbamas.
The present invention can be dissolved in ligustrazine and coating material in the solvent, and be configured to solution, be sprayed on the stainless steel stent with accurate spray gun, for example: ligustrazine and coated polymeric-polymethacrylate copolymer are dissolved in the oxolane, be mixed with solution, be sprayed on the stainless steel stent with accurate spray gun, in 60 degree baking ovens, dry.Amount with the ligustrazine on the precision balance Weighting and Controlling support.In the undercoating outside of pastille, the spraying one deck that uses the same method contains the polymethacrylate copolymer of Polyethylene Glycol side chain, in order to improve the anticoagulant property of rack surface.
Ligustrazine is Chinese medicine commonly used, find to have obvious suppression platelet aggregation and thrombosis to generate, suppress the effect of vascular smooth muscle cell and fibroblast proliferation in cytology's test of exsomatizing and zoopery, domestic also have the oral ligustrazine of research prompting can reduce PCI postoperative restenosis incidence rate.But the present invention implants in the porcine coronary by preparation ligustrazine coating bracket, the effect of observing 28 days neointimal hyperplasia obviously being suppressed, the in-stent restenosis rate obviously reduces in the support.In the porcine coronary restenosis model, suppressed neointimal proliferation with ligustrazine coating bracket with the Chinese medicine ligustrazine preparation that suppresses the smooth muscle cell proliferation effect, reduced restenosis rate behind the stenting.The tectology inspection shows that new intima area ligustrazine coating bracket group obviously reduces than bare metal stent group, and the tube chamber area obviously increases, and stenosis is than the obvious decline 67% of matched group in the support, and late period, caliber was lost obvious decline.With in other tests or the DESs of clinical practice contrast, the stenosis reduction rate is respectively rapamycin (50%), paclitaxel (39.5%), estradiol (40%) in the support, substantially be in similar level, show that ligustrazine can reduce ISR significantly as the coating medicine of support.
This research dynamic observed the animal routine blood test in 28 days, hepatic and renal function, and TnT experimental group and matched group show no obvious abnormalities.The ventricle wall row histopathological examination of the whole body important organ heart, liver,kidney,spleen and the blood supply of support vessel segment is not found the pathological lesion relevant with TES.Check coronarography and intravascular ultrasound were not seen obvious thrombosis in 28 days.IVUS and tectology inspection show that new intima area ligustrazine coating bracket group obviously reduces than bare metal stent group, and the tube chamber area obviously increases, and the result shows that the ligustrazine coating bracket has the favorable tissue compatibility and blood compatibility.
The applicant tests ligustrazine coating bracket prevention in-stent restenosis, the present invention is that 99% the ligustrazine monomer and the compositions and the polyglycolic acid of methylmethacrylate copolymer evenly are sprayed on the bare metal stent with purity, makes the coating bracket that contains ligustrazine 200 μ g.Observe the short-term effect of support of the present invention: select 14 of healthy miniature pigs to postoperative restenosis, the row coronarography is also implanted one piece of ligustrazine coating bracket or bare metal stent (support/blood vessel=1.1-1.2/1.0) at random in the left anterior descending branch stage casing, row IVUS checks that the confirmation support is adherent good, and no local vascular interlayer, aneurysm, blood vessel intramural hematoma or angiorrhexis and bigger fresh thrombus form.The 28th day capable CAG of postoperative and IVUS check, and put to death animal row tectology inspection and calculate the PCNA index, observes the in-stent restenosis situation.
The result: 14 miniature pigs all success are wherein implanted in back 2 hours deadly for 4 at left anterior descending branch stage casing implant frame at support, all the other 10 pigs (5 of bare metal stent matched groups, 5 of ligustrazine coating bracket groups) are finished check smoothly.28 days QCA check that blood vessel diameter is compared all behind two groups of follow-up period blood vessel diameters and the support and obviously reduce (P＜0.01); Late period caliber to lose ligustrazine coating bracket group be 0.28 ± 0.08mm, (1.70 ± 0.52mm) compare obviously and reduce (P=0.004) with matched group; The narrow percentage ratio of brace sections blood vessel diameter is respectively 10.0 ± 2.1% and 60.2 ± 23.5% for two groups, and ligustrazine coating bracket group obviously reduces (P=0.01); It is 60% that matched group ISR leads, and the ligustrazine group is 0.IVUS checks that the narrow percentage ratio of average area is respectively 19.1 ± 10.5% and 71.0 ± 23.3% for two groups, and ligustrazine coating bracket group reduces by 73% (P=0.007).The tectology inspection shows two groups of blood vessel injury scorings close with the support inner area (P＞0.05), but (4.34 ± 0.93mm2) than matched group (1.29 ± 1.02mm2) obviously increases (P=0.011) for ligustrazine coating bracket group tube chamber area, (1.51 ± 0.45mm2) than matched group (4.60 ± 1.39mm2) obviously minimizings (P=0.004) for the new intima area, the narrow percentage ratio of average area (25.6 ± 5.0%) reduces by 67% (P=0.003) than matched group (77.9 ± 19.7%), the PCNA index than matched group obviously reduce (14.7 ± 2.5%vs23.6 ± 3.2%, P=0.008).Support inner area, tube chamber area, new intima area, the narrow percentage ratio all similar of average area, difference not statistically significant are compared in two groups of IVUS and tectology inspection.
Conclusion: this Success in Experiment is set up the porcine coronary restenosis model; Compare with bare metal stent, the ligustrazine coating bracket obviously reduces in-stent restenosis; The intravascular ultrasound inspection can be used as the evaluation means of restenosis research in the pig coronary restenosis model support.
Following table is 28 days quantitative coronary angiography (QCA) check results:
| Bare bracket group (n=5) | Ligustrazine coating bracket group (n=5) | The P value | |
| Behind blood vessel diameter (mm) support of basis at once caliber (mm) support/blood vessel than follow-up period blood vessel diameter (mm) | 2.52±0.31 2.90±0.26 1.13±0.02 1.20±0.77 | 2.42±0.28 2.76±0.38 1.14±0.06 2.48±0.31 | 0.631 0.525 0.607 0.032 |
| Late period, caliber was lost (mm) diameter stenosis percentage ratio (%) | 1.70±0.52 60.2±23.5 | 0.28±0.08 10.0±2.1 | 0.004 0.010 |
Following table is 28 days bare bracket groups and ligustrazine coating bracket group tectology and SABC check result:
| Bare bracket group (n=5) | Ligustrazine coating bracket group (n=5) P value | |
| Damage scoring support inner area (mm 2) tube chamber area (mm 2) new intima area (mm 2) the narrow percentage ratio of average area (%) PCNA index (%) | 1.87±0.16 6.04±1.21 1.29±1.02 4.60±1.39 77.9±19.7 23.6±3.2 | 1.82±0.13 0.274 5.85±1.24 0.613 4.34±0.93 0.011 1.51±0.45 0.004 25.6±5.0 0.003 14.7±2.5 0.008 |
The research of ligustrazine coating coronary artery bracket biocompatibility experiment:
Purpose: coating stent of medicine (DES) can significantly lower 6 months in-stent restenosis, but its advanced thrombus formation receives much concern.Adopt the extract-tetramethylpyazine of ligustrazine to make ligustrazine coating coronary artery bracket (TES), utilize the local sustained release technology to suppress in-stent restenosis as the coating of tubular metal support.But its late result and safety it be unclear that.This research is observed than major diameter TES by coronarography (CAG), intravascular ultrasound (IVUS) and histopathological examination and is inserted thrombosis and intimal proliferation situation behind the miniature pig normal coronary, and TES is to the influence of whole body important organ.Estimate its biocompatibility.
Method: experimental group: the ligustrazine coating bracket is that rustless steel 316L tubular metal support is made through spraying ligustrazine monomer, is two coatings, and internal layer is methylmethacrylate copolymer and ligustrazine granule, contains ligustrazine 200 μ g.It is outer to be polyglycolic acid (PGA) coating.Make the coating bracket that contains ligustrazine 200 μ g.Matched group is bare metal stent (BMS).14 of miniature pigs, wherein experimental group is 7,7 of matched groups.Insert than major diameter TES and BMS respectively at porcine coronary left anterior descending branch or right coronary artery, support and blood vessel diameter are than (1.1 ~ 1.2/1.0).That support is inserted is preceding, animal routine blood test, hepatic and renal function, TnT (TNT) are observed in postoperative the 1st day and blood drawing in the 28th day.Omnidistance animal blood pressure, heart rate and the behavior state observed.Before and after inserting, support all goes quantitative coronary according to shadow (QCA) and intravascular ultrasound inspection.The 28th day capable CAG of postoperative and IVUS observe intimal proliferation and thrombosis situation in the support.The experiment terminal point is put to death animal, obtains the heart, kidney, liver, lung, spleen, the support section of inserting blood vessel and 5CM place, support front and back tissue row pathological examination.
The result: 14 animals are all successfully inserted support.2 animals die from preliminary experiment because of pericardial tamponade, and 1 animal support is inserted the back because of anaesthetizing dark death.Angiorrhexis when 1 animal surgery finishes the ligation femoral artery, massive hemorrhage death.5 animals are successfully inserted TES in anterior descending branch or the nearly stage casing of right coronary artery, and 5 animals are inserted BMS, and that support is inserted is preceding, postoperative the 1st day and the 28th day animal routine blood test, hepatic and renal function no significant difference, and TNT shows no obvious abnormalities.Postoperative the 28th day check coronary angiography and intravascular ultrasound check that validating experiment group, the local tube wall of matched group are complete, and tube wall does not have ulcer, hemangioma, and no Medionecrosis is not seen thrombosis.All there is not the blood vessel spasm.Histopathological examination pointed out the heart, kidney, liver, lung, spleen not to have obvious damage after postoperative was put to death animal.All supports are inserted all complete endothelialization of sections, and TES group and BMS pack support end blood vessel all have new intima hypertrophy in various degree, and no foreign body giant cell is assembled.28 days QCA check that blood vessel diameter is compared all behind two groups of follow-up period blood vessel diameters and the support and obviously reduce (P＜0.01), the narrow percentage ratio of brace sections blood vessel diameter is respectively matched group 60.2 ± 23.5% and experimental group 10.0 ± 2.1% for two groups, and ligustrazine coating bracket group obviously reduces (P=0.01).The tectology inspection shows two groups of blood vessel injury scorings close with the support inner area (P＞0.05), but ligustrazine coating bracket group tube chamber area (4.34 ± 0.93mm2) than matched group (1.29 ± 1.02mm2) obviously increase (P=0.011), the new intima area (1.51 ± 0.45mm2) than matched group (4.60 ± 1.39mm2) obviously reduce (P=0.004).Two groups of IVUS and tectology inspection are compared, and support inner area, tube chamber area, new intima area all similar have dependency preferably.
Conclusion: TES has the effect of remarkable inhibition intimal proliferation, does not have to cause bolt, to whole body important organ non-toxic reaction, has excellent biological compatibility.IVUS conjunctive tissue pathological examination can be distinguished thrombosis and speckle, can accurately measure the new intima area, and IVUS and histopathological examination have good dependency.
With reference to Fig. 3, Fig. 4, show that at the external scanning electron microscopic observation that bracket coating is carried out before the support expansion (A, B), the ligustrazine medication coat can evenly be covered in rack surface.Sacculus pressurization expansion back (C, D) is not found to peel off coating failure, show this coating can with the support strong bonded, thereby avoid because of the coating caused vascular occlusion that separates, comes off with support, distal embolization.
Table 3: pig peripheral blood cells counting before and after support is implanted, blood parameters and TnT change
Before A:TES implants and implanted back 1 day and 28 days cytometries and TnT solubility
| Time | WBC RBC HGB TNT (109/L) (1012/L) (g/L) (ng/ml) |
| Implant before support is implanted and implanted back 28 days in back 1 day | 21.48±5.04 5.47±0.38 83.38±5.81 ＜0.03 18.37±2.54 4.98±0.56 95.3±10.2 ＜0.03 17.47±2.94 5.72±0.83 105.3±9.3 ＜0.03 |
Abbreviation: WBC, numeration of leukocyte; RBC, red blood cell count(RBC); HGB, hemoglobin; TNT, TnT .B:TES implanted before and after 1 day, 28 days biochemical index evaluations
| Time | ALT AST BUN Scr (IU/L) (IU/L) (mmol/L) (μmol/L) |
| Implant before support is implanted and implanted back 28 days in back 1 day | 34.88±17.84 51.75±10.49 3.39±0.87 106.75±11.68 33.75±15.82 50.38±8.54 3.33±0.93 102.75±12.31 38.38±12.95 51.88±8.04 3.45±0.94 105.63±12.07 |
Abbreviation: ALT, glutamate pyruvate transaminase; AST, glutamic oxaloacetic transaminase, GOT; BUN, blood urea nitrogen; Scr, serum creatinine
Table 4: the minimum arteria coronaria diameter (mm) of support vessel segment
| BMS TES P value | |
| Implant back 28 days support/blood vessel ratios before implanting | 2.52±0.31 2.42±0.28 0.631 2.90±0.26* 2.76±0.38# 0.525 1.20±0.77** 2.48±0.31## 0.032 1.13±0.02 1.14±0.06 0.607 |
* with before implanting compare P=0.001** and implant relatively P=0.002 of back
# compares P=0.002 with the preceding relatively P=0.007## of implantation and after implanting
Support implant back 28 days TMP to the influence of heart local organization and each important organ of whole body referring to Fig. 5-1～Fig. 5-6.
Claims (2)
1, a kind of coronary artery medicinal-coating stent that is used to suppress intimal proliferation and prevention in-stent restenosis, comprise: expanding support matrix (1), it is characterized in that on expanding support matrix (1), being coated with undercoating (2), above-mentioned undercoating (2) is made up of pharmaceutical carrier and ligustrazine, its mass ratio is: 3: 1～1: 3, the said medicine carrier was an acrylic acid methyl ester., methylmethacrylate copolymer, polylactic acid (PLLA), polyglycolic acid, poly--racemic lactic acid, polylactide-co-glycolide polymers, Phosphorylcholine, poly-aethylis carbamas, inorganic micropore aluminium sesquioxide, the compositions of one or more in the cellulose.
2, coronary artery medicinal-coating stent according to claim 1, it is characterized in that being coated with on undercoating (2) external coating (3), this external coating (3) is one or more the composition coating in acrylic acid methyl ester., methylmethacrylate copolymer, polylactic acid (PLLA), polyglycolic acid, poly--racemic lactic acid, polylactide-co-glycolide polymers, Phosphorylcholine, the poly-aethylis carbamas.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610096840 CN100493627C (en) | 2006-10-20 | 2006-10-20 | Coronary artery medicinal-coating stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610096840 CN100493627C (en) | 2006-10-20 | 2006-10-20 | Coronary artery medicinal-coating stent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1935274A true CN1935274A (en) | 2007-03-28 |
| CN100493627C CN100493627C (en) | 2009-06-03 |
Family
ID=37953129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610096840 Expired - Fee Related CN100493627C (en) | 2006-10-20 | 2006-10-20 | Coronary artery medicinal-coating stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100493627C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397119A (en) * | 2011-09-29 | 2012-04-04 | 微创医疗器械(上海)有限公司 | Interventional medical appliance and manufacturing method thereof |
| CN102499798A (en) * | 2011-09-29 | 2012-06-20 | 微创医疗器械(上海)有限公司 | Interventional medical device and preparation method thereof |
| CN105877881A (en) * | 2015-03-03 | 2016-08-24 | 周玉杰 | Method for preparing personalized bionic drug eluting coronary stent by using 3D printing technology |
| CN108452392A (en) * | 2018-03-28 | 2018-08-28 | 周胜华 | A kind of newtype drug coating bracket and preparation method thereof |
| CN110283296A (en) * | 2019-06-20 | 2019-09-27 | 中国科学院长春应用化学研究所 | Difunctional polyurethane and the preparation method and application thereof |
| CN113425913A (en) * | 2021-06-17 | 2021-09-24 | 江阴市人民医院 | Functional appliance for thoracic surgery |
-
2006
- 2006-10-20 CN CN 200610096840 patent/CN100493627C/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397119A (en) * | 2011-09-29 | 2012-04-04 | 微创医疗器械(上海)有限公司 | Interventional medical appliance and manufacturing method thereof |
| CN102499798A (en) * | 2011-09-29 | 2012-06-20 | 微创医疗器械(上海)有限公司 | Interventional medical device and preparation method thereof |
| WO2013044603A1 (en) * | 2011-09-29 | 2013-04-04 | 上海微创医疗器械（集团）有限公司 | Interventional medical device and manufacturing method thereof |
| US20140248327A1 (en) * | 2011-09-29 | 2014-09-04 | Shanghai Microport Medical (Group) Co., Ltd. | Interventional medical device and manufacturing method thereof |
| US20150209485A1 (en) * | 2011-09-29 | 2015-07-30 | Shanghai Microport Medical (Group) Co., Ltd. | Interventional medical device and manufacturing method thereof |
| US9433709B2 (en) * | 2011-09-29 | 2016-09-06 | Shanghai Microport Medical (Group) Co., Ltd. | Interventional medical device and manufacturing method thereof |
| CN105877881A (en) * | 2015-03-03 | 2016-08-24 | 周玉杰 | Method for preparing personalized bionic drug eluting coronary stent by using 3D printing technology |
| CN108452392A (en) * | 2018-03-28 | 2018-08-28 | 周胜华 | A kind of newtype drug coating bracket and preparation method thereof |
| CN110283296A (en) * | 2019-06-20 | 2019-09-27 | 中国科学院长春应用化学研究所 | Difunctional polyurethane and the preparation method and application thereof |
| CN113425913A (en) * | 2021-06-17 | 2021-09-24 | 江阴市人民医院 | Functional appliance for thoracic surgery |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100493627C (en) | 2009-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100493627C (en) | Coronary artery medicinal-coating stent | |
| US8591931B2 (en) | Coronary stent with asymmetric drug releasing controlled coating | |
| CN105816921A (en) | Bionic vascular stent and preparation method thereof | |
| WO2002094335A1 (en) | Medicated stents for the treatment of vascular disease | |
| Mosseri et al. | The titanium-NO stent: results of a multicenter registry | |
| US20040213826A1 (en) | Medical devices and methods for inhibiting proliferation of smooth muscle cells | |
| Wei et al. | REDV/Rapamycin-loaded polymer combinations as a coordinated strategy to enhance endothelial cells selectivity for a stent system | |
| CN101485902B (en) | Biological degradable metal stent coated with rapamycin-probucol composite medicament | |
| Wang et al. | An ex vivo physiologic and hyperplastic vessel culture model to study intra-arterial stent therapies | |
| Chen et al. | High nitrogen stainless steel drug-eluting stent-Assessment of pharmacokinetics and preclinical safety in vivo | |
| Pan et al. | Recent advances in surface endothelialization of the magnesium alloy stent materials | |
| CN101279112A (en) | Intravascular stent with PLGA blend medicament eluting surface coating | |
| CN102091355A (en) | Compound coating coronary medicament eluting stent and preparation method thereof | |
| Liu | Improving the hemocompatibility of stents | |
| Zhao et al. | Application of Mg-based alloys for cardiovascular stents | |
| US20120150282A1 (en) | Implant having a paclitaxel-releasing coating | |
| CN106620897B (en) | A kind of endoluminal stent material of anti-restenosis | |
| US20050214343A1 (en) | Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis | |
| JP2005538756A (en) | Medical device comprising a protein-tyrosine kinase inhibitor for inhibiting restenosis | |
| CN108014379B (en) | Surface modification method for improving corrosion resistance of magnesium alloy intravascular stent | |
| CN104707185A (en) | Ginkgolide B composite medicine eluting stent | |
| Guo et al. | In vivo evaluation of a novel dexamethasone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis | |
| CN101836910A (en) | Biodegradable rapamycin-prednisone composite medicinal coat metal stent | |
| Galloni et al. | Carbon-coated stents implanted in porcine iliac and renal arteries: histologic and histomorphometric study | |
| CN201453424U (en) | Cardiovascular composite coating drug eluting stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090603 Termination date: 20121020 |